Please provide your email address to receive an email when new articles are posted on . IVUS may improve care of patients undergoing peripheral revascularization. More data are needed to document ...

New clinical results highlight the need for inclusive approaches and comprehensive examinations of treatment options for peripheral artery disease (PAD), including endovascular therapy and ...

"Our findings highlight the clinical importance of focusing on total disease burden, rather than first events, and the need for long-term preventive strategies in high-risk patients."—Michael Szarek, ...

Please provide your email address to receive an email when new articles are posted on . Among patients with peripheral artery disease who had an endovascular procedure, treatment with a drug-coated ...

Measured one way, success for peripheral vascular intervention (PVI) in the femoropopliteal arteries for patients with intermittent claudication has improved, as the need for repeat PVI appears to be ...

The FDA approved the LimFlow system designed to stave off amputation for people with chronic limb-threatening ischemia (CLTI) and no treatment alternatives, device maker LimFlow SA announced Tuesday.

Treatment with rivaroxaban plus aspirin significantly reduced the risk of major adverse limb and cardiovascular events in the VOYAGER PAD study. A supplemental New Drug Application (sNDA) for ...

Rivaroxaban, in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients ...

Assessing Long-Term Outcomes of Tirzepatide and Semaglutide in Heart Failure With Preserved Ejection Fraction: A Retrospective Cohort Analysis From TrinetX Database Receive the the latest news, ...

Dr. Faris Galambo is a board-certified interventional and diagnostic radiologist at the University of Utah, where he serves as Associate Program Director of the Integrated IR/DR Residency. His ...